Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Viatris Inc.NASDAQ: VTRS

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 38.8%

Gross margin was 38.8% in Q2 FY2026, up 1.6 pp from a year earlier. On a trailing-twelve-month basis it was 34.8%, down 1.8 pp year over year. Over 3 fiscal years it narrowed by 4.9 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
38.8%+5.9 pp QoQ
Last fiscal yearDec 2025
35.1%-3.1 pp YoY
LTMJun 2026
34.8%-1.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.6 pp——
1 year-3.1 pp——
3 years-4.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
35.1%
Year-over-year change
-3.1pp

Gross Margin vs competitors

How VTRS compares with its peers on the latest reported figures

  • VTRS's LTM Jun 2026 gross margin of 34.8% is the lowest of the 10 companies compared; the peer median is 53.4%.
  • Its year-over-year change of -1.8 pp is the 6th highest of 9, against a peer median of -0.3 pp.
  • Over three fiscal years its change of -4.9 pp compares with a peer median of -0.3 pp.
VTRS Competitors Peer median
Gross Margin for VTRS and competitors
Company Period LTM level YoY 3-year change
ALKSAlkermes plcLTM Sep 202682.9% -3.2 pp+6.3 pp
BHCBausch Health Companies Inc.LTM Jun 202671.8% +1.1 pp-0.3 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202665.9% +6.6 pp-5.1 pp
HLNHaleon plcLTM Jun 202563.2% —+2.8 pp
OGNOrganon & Co.LTM Sep 202653.4% -1.6 pp-8.8 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202652.5% +2.9 pp+5.1 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202649.5% -7.0 pp-3.9 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.3% -3.3 pp-0.4 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202639.3% +1.7 pp+1.9 pp
VTRSViatris Inc.LTM Jun 202634.8% -1.8 pp-4.9 pp
Peer median (excluding VTRS) 53.4%-0.3 pp-0.3 pp

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.89B16.26B15.43B14.74B14.3B
Cost of Revenue12.31B9.77B8.99B9.12B9.29B
Gross Profit5.58B6.5B6.44B5.62B5.01B
Gross Margin31.2%40.0%41.7%38.2%35.1%
Research & Development681M662.2M805.2M808.7M965.9M
Selling, General & Admin4.53B4.18B4.65B4.43B3.79B
Operating Expenses5.61B4.88B5.67B5.61B7.68B
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
EBITDA4.48B6.43B3.52B2.64B(395.4M)
EBITDA Margin25.0%39.6%22.8%17.9%-2.8%
Operating Income(34M)1.61B766.2M10.1M(2.66B)
Operating Margin-0.2%9.9%5.0%0.1%-18.6%
Interest Income00000
Interest Expense636.2M592.4M573.1M550M471.3M
Other Income / Expenses(630.4M)1.2B(563.3M)(633.3M)(1B)
Income Before Tax(664.4M)2.81B202.9M(623.2M)(3.67B)
Pre-Tax Margin-3.7%17.3%1.3%-4.2%-25.6%
Income Tax Expense604.7M734.6M148.2M11M(150.1M)
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Net Margin-7.1%12.8%0.4%-4.3%-24.6%
EPS (Basic)(1.05)1.710.05(0.53)(3.00)
EPS (Diluted)(1.05)1.710.05(0.53)(3.00)
Weighted Avg Shares1.21B1.21B1.2B1.19B1.17B
Weighted Avg Shares (Diluted)1.21B1.22B1.21B1.19B1.17B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.